Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206

NCT01954589 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

56

Enrollment

INDUSTRY

Sponsor class

Conditions

Safety
Tolerability
Pharmacodynamics
Pharmacokinetics

Interventions

DRUG: ACT-462206 5 mg
DRUG: ACT-462206 25 mg
DRUG: ACT-462206 100mg
DRUG: ACT-462206 200mg
DRUG: ACT-462206 400mg
DRUG: ACT-462206 1000 mg
DRUG: ACT-462206 1500mg
DRUG: Almorexant 400mg
DRUG: Placebo

Sponsor

Idorsia Pharmaceuticals Ltd.